

1 March 2010

Darren Collins  
Senior Adviser, Issuers and Accounting Policy  
Australian Stock Exchange  
525 Collins Street  
Melbourne 3000

Dear Darren

**Sigma Pharmaceuticals Limited – Request for Suspension**

Pursuant to Listing Rule 17.2, Sigma Pharmaceuticals Limited (ACN 088 417 403) (ASX: SIP) ("**Sigma**") requests that the ASX grant a suspension from trading of its securities effective immediately.

For the purposes of ASX Listing Rule 17.2, Sigma provides the following information:

- 1 the suspension is necessary as Sigma expects to make an announcement to the market in relation to revised earnings guidance for the year ended 31 January 2010.
- 2 Sigma expects that the suspension remain in place until Sigma makes an announcement concerning revised earnings guidance for the year or requests that the suspension be lifted;
- 3 Sigma expects to make an announcement to the market concerning the revised earnings guidance before the expected date for the release of its preliminary final results; and
- 4 Sigma is not aware of any reason why the suspension should not be granted.

If you have any queries, please do not hesitate to contact the writer.

Yours sincerely



Sue Morgan-Dethick  
**GENERAL COUNSEL AND COMPANY SECRETARY**